Marlborough

UMass Memorial Medical Center is seeking a minority stake in Quest Diagnostics Massachusetts LLC, according to documents filed by both organizations with the Massachusetts Health Policy Commission.

Marlborough could soon have 150 new jobs in the city with Bedford-based Hologic Inc. announcing a desire to move its headquarters to Marlborough.

RXi Pharmaceuticals of Marlborough, which is pushing toward regulatory approval of its signature anti-scarring drug, saw a slight increase in revenue and cut its losses in the first quarter, the company said Wednesday.

Worcester-based Spectrum Health Systems announced the opening of a peer recovery center in downtown Lawrence to serve people trying to overcome addictions, the third such center the addiction treatment services provider operates in the Bay State. The Lawrence Peer Recovery Center, also known as New Beginnings, uses the same peer-support model employed at centers in Worcester and Marlborough, the company said. It's expected to serve 100 residents of Lawrence, Haverhill, North Andover and other nearby communities, offering peer-driven support groups, recreational activities, social events and volunteer opportunities to those who have completed more intensive addiction treatment programs.

In the face of stagnant interest rates, investors looking for long-term returns are dropping their money into commercial real estate filled with tenants holding long-term leases.

ReWalk Robotics, the Marlborough-based maker of exoskeleton systems for paraplegics, boosted its revenue in the first quarter, according to an earnings statement. Sales, though, came up short, according to CEO Larry Jasinski.

Corporate giants such as GE Healthcare Life Sciences and Boston Scientific have lifted Marlborough's profile as a prime destination for businesses by making the city their home in the last couple of years. But local economic development leaders don't want to leave the small players in the dust.

Oxford Immunotec Global PLC, a diagnostics company with U.S. headquarters in Marlborough, announced revenue and profit growth in the first quarter of 2015.

A new study has affirmed encouraging results for treating macular degeneration using Ocata Therapeutics' stem-cell line RPE, the Marlborough company reported

Marlborough-based Boston Scientific Corp. reported adjusted first-quarter earnings of 21 cents per share Tuesday, a penny higher than for the first quarter of 2014, and at the high end of the company's projection of 19 to 21 cents.